Edwards Lifesciences (EW) Research & Development (2009 - 2026)

Edwards Lifesciences has reported Research & Development for 18 years, with the latest figure at $278.9 million in Q2 2026.

• On a quarterly basis, Research & Development rose 0.98% year-over-year to $278.9 million in Q2 2026; TTM through Jun 2026 was $1.1 billion, a 3.35% increase from a year earlier, with the FY2025 full-year figure at $1.1 billion, up 2.49% from the prior year.
• Research & Development was $278.9 million for Q2 2026 at Edwards Lifesciences, up from $263.3 million in the prior quarter.
• The five-year high for Research & Development was $280.7 million in Q3 2025, with the low at $130.6 million in Q4 2022.
• Average Research & Development over 5 years is $250.4 million, with a median of $255.6 million recorded in 2024.
• The sharpest annual moves came in 2022 and 2023: Research & Development sank 43.9% in 2022, then soared 85.38% in 2023.
• Over 5 years, Research & Development stood at $130.6 million in 2022, then surged by 85.38% to $242.1 million in 2023, then grew by 11.98% to $271.1 million in 2024, then fell by 1.25% to $267.7 million in 2025, then grew by 4.18% to $278.9 million in 2026.
• The last three Research & Development figures came in at $278.9 million (Q2 2026), $263.3 million (Q1 2026), and $267.7 million (Q4 2025), per Business Quant data.